Canadian Solar Inc. (NASDAQ:CSIQ) reported Q3 earnings of $1.75 per share, up sharply over year ago earnings of $0.56 per share. The Street consensus on Cap IQ called for earnings of $1.14 per share, but it's unclear if this is comparable. Revenue was $914.3 million, up from $490.8 million in the year ago quarter and ahead of expectations of $803 million.For Q4, Canadian Solar Inc. (NASDAQ:CSIQ) expects module shipments to be in the range of approximately 810 MW to 860 MW. Total revenue for Q4 of 2014 is expected to be in the range of $925 million to $975 million, with gross margin expected to be between 17% and 19%. The Street view is $977 million in revenue. The gross margin guidance for the fourth quarter of 2014 factors in the impact of the U.S. trade case, the appreciation of the U.S. dollar, and the mix of project sales expected to close in Canada. For full year 2014, the company is increasing its annual module shipment guidance to be in the range of 2.73 GW to 2.78 GW, compared to a range of 2.5 GW to 2.7 GW previously. The company is also increasing its revenue guidance for 2014 to the range of approximately $2.93 billion to $2.98 billion, compared to a range of $2.7 billion to $2.9 billion previously. The Street view is $2.85 billion.Click here for a free comprehensive Trend Analysis ReportAtara Biotherapeutics Inc (NASDAQ:ATRA), a biopharmaceutical development company with a focus on debilitating diseases, reported a wider quarterly loss year-over-year on increased research and development costs. Atara Biotherapeutics Inc (NASDAQ:ATRA) reported Q3 adjusted EPS of $4.20, wider than the loss of $2.59 reported in the same period a year ago and wider than the loss of $2.25 predicted by analysts, if comparable. The company reported no revenues. Analysts made no revenue predictions for the quarter.Research and development expenses, including costs paid to Amgen, Inc., increased to $4.2 million for Q3, compared to $1.7 million for Q3 2013, driven primarily by the option and related costs paid to Memorial Sloan Kettering Cancer Center in September 2014 and higher costs related to expanded clinical development activities and increased headcount. Shares of ATRA are at $27.21 within a 52-week range of $9.66 - $29.48.Click here for a free comprehensive Trend Analysis ReportEscalade, Inc. (NASDAQ:ESCA) is higher after the company reported that for Q3 ended Oct. 4, 2014, earnings topped analysts' expectations, while revenue fell short. The company also declared a quarterly dividend and named a new chief financial officer. Shares are up 7.6% at $12.22 with a 52-week range of $8.95 - $17.20. The manufacturer of sporting goods posted Q3 net income of $13.6 million or $0.27 per share, compared with the prior-year period's $2.5 million or $0.24 per share. Revenue was $31.6 million, up from $31.56 million in the same quarter last year.Analysts polled by Capital IQ were expecting EPS of $0.16 on revenues of $31.9 million. The company's board of directors declared a quarterly dividend on the company's common stock of $0.10 per share, to be paid to all shareholders of record on Dec. 12, 2014 and disbursed on Dec. 19, 2014. This was maintained from the previous quarter's dividend paid on Sept. 21, 2014. Separately, Escalade, Inc. (NASDAQ:ESCA) said that it will be consolidating its finance and accounting department effective at the end of its fiscal year on Dec. 27, 2014.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
